To include your compound in the COVID-19 Resource Center, submit it here.

Indel: Vive la difference

Indel going after drug-resistant bacteria with new targets

Bacterial proteins that have close homologs in humans have largely been ignored as drug targets due to safety concerns. Indel Therapeutics Inc. thinks it has a way to safely target these proteins, opening up a new field of targets for infectious diseases. The company is starting with drug-resistant bacteria.

The Indel platform technology, which it licensed out of the University of British Columbia, identifies specific amino acid sequences that differ between the human and

Read the full 739 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers